Ikarian Capital, LLC Elevation Oncology, Inc. Transaction History
Ikarian Capital, LLC
- $714 Million
- Q1 2025
A detailed history of Ikarian Capital, LLC transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 690,050 shares of ELEV stock, worth $262,219. This represents 0.03% of its overall portfolio holdings.
Number of Shares
690,050
Previous 690,050
-0.0%
Holding current value
$262,219
Previous $400,000
55.25%
% of portfolio
0.03%
Previous 0.07%
Shares
5 transactions
Others Institutions Holding ELEV
# of Institutions
74Shares Held
34.6MCall Options Held
65KPut Options Held
4K-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$2.28 Million0.1% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5.89MShares$2.24 Million1.24% of portfolio
-
Tang Capital Management LLC San Diego, CA4.76MShares$1.81 Million0.08% of portfolio
-
Aisling Capital Management LP New York, NY2.83MShares$1.08 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.59MShares$982,3830.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $8.85M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...